Table 3 Identified organisms from cultures and their susceptibilities.

From: Extended infusion of piperacillin–tazobactam versus intermittent infusion in critically ill egyptian patients: a cost-effectiveness study

Variable

Intermittent (n = 27)

Extended (n = 26)

P-value

Sputum, n (%) a

17 (63%)

20 (77%)

0.268

Positive cultures

10/17 (59%)

10 /20 (50%)

0.591

K.pneumoniae

1/10 (10%)

3/10 (30%)

 

Acinetobacter spp

Providencia spp.

1/10 (10%)

NA

1/10 (10%)

1/10 (10%)

 

P.aeruginosa

S.auerus

Enterobacter spp.

Other Gram

Negative bacteria

NA

NA

NA

8/10 (80%)

1/10 (10%)

1/10 (10%)

1/10 (10%)

2/10 (20%)

 

Blood, n (%) b

11 (41%)

9 (35%)

0.645

Positive cultures

2/11 (18%)

1/9 (11%)

0.651

Other Gram

negative bacteria

2/2 (100%)

1/1 (100%)

 

Wound, n (%) b

6 (22%)

2 (8%)

0.139

Positive cultures

2/6 (33%)

2/2 (100%)

0.102

S.auerus

K.Pneumoniae

Other Gram

negative bacteria

1/2 (50%)

1/2 (50%)

1/2 (50%)

1/2 (50%)

 

Urine, n (%) b

13 (48%)

7 (27%)

0.111

Positive cultures

4/13 (25%)

6/7 (86%)

0.019

P.aeruginosa

K.pneumoniae

S.auerus

Escherichia coli

Other Gram

negative bacteria

1/4 (25%)

NA

NA

NA

3/4 (75%)

NA

1/6 (16.6%)

1/6 (16.6%)

1/6 (16.6%)

3/6 (50%)

 
  1. Results are expressed as mean ± SD or number (%) and were compared using a chi-square test or b Fisher’s exact test where appropriate. P-value ≤ 0.05 is considered statistically significant.